从 DEL 筛选中分离 NKG2D 命中。针对位点选择性固定化 Natural Killer Group 2D (NKG2D) 筛选了包含总共超过 100 万种化合物的紧凑型单药团双结构单元 DNA 编码化学文库 (DEL)。在 DEL 选择实验后优先富集的化合物17被鉴定并验证为 NKG2D 的配体,其亲和常数在纳摩尔范围内。
SYNTHESIS, STRUCTURE AND USE OF BISOXAZOLIDINES FOR ASYMMETRIC CATALYSIS AND SYNTHESIS
申请人:Wolf Christian
公开号:US20070265255A1
公开(公告)日:2007-11-15
One aspect of the invention relates to chiral bisoxazolidines and their use in asymmetric catalysis. The chiral bisoxazolidines are a novel class of compounds that is expected to find multiple applications, for example, in asymmetric synthesis. For example, a bisoxazolidine ligand enabled the catalytic enantioselective alkynylation and alkylation of a range of aromatic and aliphatic aldehydes, generating chiral propargylic alcohols and secondary alcohols in high yields and enantiomeric excess.
[EN] FAP-ACTIVATED THERAPEUTIC AGENTS, AND USES RELATED THERETO<br/>[FR] AGENTS THÉRAPEUTIQUES ACTIVÉS PAR FAP, ET UTILISATIONS ASSOCIÉES
申请人:TUFTS COLLEGE
公开号:WO2015192123A1
公开(公告)日:2015-12-17
Disclosed are prodrugs of cytotoxic anthracyclines (such as doxorubicin) and other therapeutic agents that are selectively cleaved and activated by fibroblast activating protein (FAP). The prodrugs are useful for targeted delivery of cytotoxic and other agents to FAP- expressing tissues, including cancer (e.g., solid tumors). Also provided are pharmaceutical compounds comprising the prodrugs, as well as methods of using the prodrugs to treat a disorder characterized by FAP upregulation, e.g., cancer, fibrosis, and inflammation.
[EN] COMPOSITIONS AND METHODS FOR INHIBITING VIRAL POLYMERASE<br/>[FR] COMPOSITIONS ET PROCÉDÉS D'INHIBITION D'UNE POLYMÉRASE VIRALE
申请人:BIOCRYST PHARM INC
公开号:WO2013158746A1
公开(公告)日:2013-10-24
Provided are compounds of Formula (I) as described herein. Compounds of Formula (I) are useful in methods of inhibiting viral RNA polymerase activity and viral replication. Also provided are pharmaceutical compositions comprising compounds of Formula (I), as well as methods of treating viral infections using compounds of Formula (I).
Process for the preparation of enantiomerically enriched indoline-2-carboxylic acid
申请人:DSM IP Assets B.V.
公开号:EP1676838A1
公开(公告)日:2006-07-05
The present invention relates to a process for the preparation of an enantiomerically enriched optionally substituted indoline-2-carboxylic acid or a salt thereof, said process comprising subjecting an enantiomerically enriched chiral 2-amino-3-(2-X-substituted aryl)-propionic acid or 2-yl-substituted-amino -3-(2-X-substituted aryl)-propionic acid or a salt thereof, wherein X is a leaving group, to cyclisation, preferably at a temperature of below about 140°C, and in case of the yl-substituted compound, removing said yl-substituent by hydrolysis either prior to or after said cyclisation.
[EN] PROTEOGLYCAN MIMETICS FOR ENHANCED WOUND HEALING, ANGIOGENESIS, AND VASCULAR REPAIR<br/>[FR] MIMÉTIQUES DE PROTÉOGLYCANE POUR UNE CICATRISATION, UNE ANGIOGENÈSE ET UNE RÉPARATION VASCULAIRE AMÉLIORÉES
申请人:UNIV CALIFORNIA
公开号:WO2019195780A1
公开(公告)日:2019-10-10
The present disclosure provides pro-angiogenic proteoglycan mimetics that can provide a provisional, pro-angiogenic scaffold to support tissue regeneration while limiting systemic exposure to VEGF activity. These mimetics can protect a collagen matrix from rapid degradation, and in conjunction with EPCs promote angiogenesis in order to accelerate ischemic wound healing. For example, the provided compounds can be delivered from the end of a catheter following balloon angioplasty to coat the collagen exposed areas, prevent platelet binding and thrombosis, support capture of EPCs from blood to facilitate reendothelialization, and reduce late-lumen loss (neointimal hyperplasia).